MetaCap

AC Immune SA (ACIU) vs AN2 Therapeutics (ANTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

AN2 Therapeutics (ANTX) has outperformed AC Immune SA (ACIU) over the past year, gaining 366.1% versus a loss of 35.0%. AC Immune SA is the larger company by market cap ($193.9 million vs $192.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACIU-35.00%ANTX+366.06%
+502%+221%-61%
Nov 21, 20251 yearNov 20, 2026
ACIU-55.68%ANTX-67.01%
+42%-29%-100%
Mar 21, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACIU versus ANTX key metrics
MetricACIUANTX
Share price$1.95$5.08
Market cap$193.88M$192.75M
1-day change-8.45%-2.68%
YTD return-37.90%+345.61%
1-year return-35.00%+366.06%
5-year return-62.28%—
Forward P/E2.84—
EPS (TTM)$-0.44$-0.91
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-35.17M
52-week high$3.90$7.19
52-week low$1.93$1.00
Distance from 52-week high-50.00%-29.35%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+331.28%+77.17%
Average volume198.81K289.29K
Shares outstanding99.43M37.94M
Employees9021
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANTX has outperformed ACIU by 401.1 percentage points over the past year.

About AC Immune SA

ACIU stock →

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees

About AN2 Therapeutics

ANTX stock →

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

ACIU vs ANTX FAQ

Which is bigger, AC Immune SA or AN2 Therapeutics?

AC Immune SA (ACIU) is larger, with a market capitalization of $193.88M compared with $192.75M for AN2 Therapeutics (ANTX).

Which stock has performed better over the past year, ACIU or ANTX?

ANTX returned +366.06% over the past 12 months, compared with -35.00% for ACIU (price return, excluding dividends). Past performance does not predict future results.

Are AC Immune SA and AN2 Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons